What is the Market's View on Innoviva Inc (INVA) Stock's Price and Volume Trends Wednesday?

Innoviva Inc (INVA) stock has fallen 2.16% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Innoviva Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on INVA!

See Full INVA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With INVA Stock Today?

Innoviva Inc (INVA) stock is trading at $13.57 as of 11:33 AM on Wednesday, Nov 22, an increase of $0.14, or 1.04% from the previous closing price of $13.43. The stock has traded between $13.46 and $13.63 so far today. Volume today is less active than usual. So far 78,597 shares have traded compared to average volume of 717,147 shares. To see InvestorsObserver's Sentiment Score for Innoviva Inc click here.

More About Innoviva Inc

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. Click Here to get the full Stock Report for Innoviva Inc stock.